Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study-MedSci.cn

Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

Schmid, P; Wysocki, PJ; Ma, CX; Park, H; Fernandes, R; Lord, S; Baird, RD; Prady, C; Jung, KH; Asselah, J; Huisden, R; Stewart, R; Heider, K; Vukovic, P; Denduluri, N; Nowecki, Z

ANNALS OF ONCOLOGY, 2023; 34 (): S337

科室
- - 订阅+
  - 更多科室
工具
服务